share_log
Reuters ·  Mar 19 09:19
Shanghai Henlius Biotech - Orphan-Drug Designation of Hlx22 (Recombinant Humanized- Anti-Her2 Monoclonal Antibody Injection) Granted by US FDA
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 311

Recommended

Write a comment